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ABSTRACT: Metallodrug−protein interactions contribute to their therapeutic eﬀect
(even when DNA is the dominant target), side-eﬀects and are implicit in drug
resistance. Here, we provide mass spectrometric-based evidence to show that
metallodrug interactions with proteins are considerably more complex than current
literature would suggest. Using native-like incubation and electrospray conditions
together with an automated tool we designed for exhaustive mass spectra matching, the
promiscuity of binding of cisplatin to ubiquitin is revealed, with 14 diﬀerent binding
sites observed. There is a binding preference to negatively charged sites on the protein,
consistent with the cationic nature of the cisplatin adduct following aquation. These
results have implications in metallodrug development and beyond to the toxicological
eﬀects of metal ions more generally.
The interaction of metal ions with proteins is important asmany endogenous proteins utilize metals for stabilization
or activity.1 Metal complexes are also used therapeutically for
the diagnosis or treatment or various diseases,2 and certain
metal ions are also implicated in toxicity and diseases.3 Many
techniques have been used to study metal−protein inter-
actions4−6 and mass spectrometry (MS) has been particularly
valuable,7−17 leading to the ﬁeld of metallomics.18 Notably, the
application of top-down tandem MS, where whole proteins are
directly sprayed into the mass spectrometer and then
fragmented (MS/MS),19,20 has been extremely useful in
identifying binding sites of metallodrugs. Various metal−
protein interactions have been probed by the application of
top-down MS.8,10,11,14−16,21,22 However, a signiﬁcant challenge
of this approach is to interpret the complicated mass spectra
generated where typically thousands of peaks are present, and
manual identiﬁcation is extremely diﬃcult (due to the vast
number of complex and overlapping isotopic patterns observed
from metal species adducted to peptide fragments), prone to
error, and often only the most intense peaks are assigned. In
this context, previous studies do not use internal fragment ions
generated by CID to assign metalation sites.
To overcome this limitation, we developed an automated
tool, termed Analysis of Protein Modiﬁcations from Mass
Spectra (Apm2s), a free and versatile web-based tool based on
chemcalc (http://ms.cheminfo.org/apm2s/index.html).23 This
tool calculates all possible theoretical mass spectra of a given
protein/peptide sequence with any user deﬁned modiﬁcations
(e.g., post translational modiﬁcations, ligands, metal ions) and
matches each individual isotopic peak to experimental mass
spectra to generate a list of matches with similarity scores24
(matching algorithm described in further detail in the SI).
Using this tool to decipher the binding sites of cisplatin
incubated with ubiquitin, chosen as an extensively studied
system, we discovered that far more potential binding sites exist
than current MS studies have identiﬁed.
Clinically, cisplatin is one of the most widely used cancer
chemotherapy agents,25,26 and MS-based studies of its binding
to the 8.5 kDa protein ubiquitin (Ubi) have been performed
previously by MS.21,27,28 The binding of cisplatin to either
unmodiﬁed and oxidized ubiquitin was compared revealing that
oxidation of the Met1 residue reduced cisplatin binding,
indicating Met1 is a potentially important binding site.27 This
binding site was subsequently conﬁrmed in a top-down study
where platinated fragments containing Met1 were identiﬁed
when the cisplatin-ubiquitin adduct was fragmented by either
collisional induced dissociation (CID) and infrared multi-
photon dissociation (IRMPD).21 A bottom-up study of the
same system has also been performed identifying up to four
diﬀerent binding sites, Met1, Thr12, Thr14, and Asp32.28
These previous studies provided us a basis for comparing our
own results using the automated tool.
■ EXPERIMENTAL SECTION
Materials. Ubiquitin from bovine erythrocytes and
myoglobin from equine skeletal muscle was purchased from
Sigma-Aldrich (Product number U6253 and M0630 respec-
tively) and cisplatin was purchased from Tokyo Chemical
Industries. MS grade LysylC and GluC endoproteinase were
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purchased from Thermo Fisher Scientiﬁc, U.S.A. RAPTA-C
was synthesized from a literature procedure.29
Sample Preparation. Ubiquitin (100 μM) was incubated
with cisplatin in 1:1, 1:5 and 1:30 protein:drug ratios at 37 °C
for 0.5 to 18 h. Myoglobin (10 μM) was incubated with
RAPTA-C in 1:3 ratio at 37 °C for 24 h. All incubations were
performed in sterile MilliQ water. Excess drug was removed
with three rounds of centrifugation using 3 kDa-cutoﬀ Amicon
Ultra centrifugal ﬁlters according to manufacturer’s instructions.
Incubated proteins were snap frozen in liquid N2 and stored at
−20 °C prior to MS/MS analysis. For bottom-up sample
preparation, metallodrug−protein incubations were digested
with MS grade LysylC according to manufacturer’s instructions.
In brief, incubation of ubiquitin with each enzyme was
performed at a ratio of 1:50 in a 5 mM ammonium carbonate
pH 8 buﬀer, for 8 h at 37 °C.
Mass Spectrometry Analysis. CID fragmentation studies
were performed on an ETD enabled hybrid linear ion trap
(LTQ) Orbitrap Elite mass spectrometer (Thermo Scientiﬁc,
Bremen, Germany) coupled to a Triversa Nanomate (Advion)
chip-based electrospray system. For top-down experiments,
samples were diluted in water and directly infused. For bottom-
up samples, dilutions were performed in CH3CN/H2O/
HCOOH (50:49.9:0.1) before infusion. Spray voltage used
was 1.6 kV and the automatic gain control (AGC) target was
set to 1 × 106 for full scans in the Orbitrap mass analyzer.
Precursor ions for MS/MS were detected in the Orbitrap at a
resolving power of 30000 (at 400 m/z) with an isolation width
of 8, and product ions were transferred to the FT-MS operated
Figure 1. Top-down MS/MS from the CID fragmentation of the [7H + Ubi + PtN2H6]
9+ and [8H + Ubi + PtN2H8O]
10+ ions. (A) Explanation of
the internal fragment nomenclature of the Apm2s tool. Internal fragment named (N-terminal fragment, C-terminal fragment) and corresponds to the
regions which overlap between the N and C terminal fragments. (B) MS/MS spectra with detected metalated fragments labeled (terminal fragments
in blue and internal fragments in red). Location of metalated fragments in full length ubiquitin is shown below each spectra and similarly color coded
with adduct type and calculated similarity score in brackets (only metalated fragments with <20 amino acid residues are shown for clarity).
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Figure 2. Most likely binding sites of the platinum(II) ion on bovine ubiquitin. Crystal structure of bovine ubiquitin in green with likely binding
residues represented in stick ﬁgures (top) and full amino acid sequence of bovine ubiquitin with predicted binding sites highlighted in red (bottom).
Figure 3. (A) Classiﬁcation of N-ter, C-ter, and M fragments. Full sequence of ubiquitin with classiﬁcation on top with examples in each row. N-
terminal fragments from residue 1−39 named N-ter (in red), fragments from residues 40−76 named C-ter (in blue), and all other fragments named
M (containing both blue and red). (B) Percentage abundance of N-ter, C-ter, and M fragment ions from CID fragmentation of free ubiquitin (top)
and platinated ubiquitin at a 1:1 protein: drug ratio (bottom) following 18 h incubation at 37 °C. (C) Percentage abundance of CID fragments
classiﬁed into diﬀerent amino acid lengths from CID fragmentation of free ubiquitin and platinated ubiquitin (similar incubation conditions as
above). Parents ions [9H+ Ubi]9+, [10H+ Ubi]10+, [7H+ Ubi + PtN2H6]
9+, [8H+ Ubi + PtN2H8O]
10+ were used for the fragmentation study.
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with an AGC of 5 × 104 over a m/z range of 200−3000. For
CID and HCD fragmentation, normalized collision energies of
20−35% and 23% respectively were used. A total of 100 scans
and 10 μscans were acquired in reduced proﬁle mode and
averaged for each fragmentation spectra. Spectra was exported
using Thermo Xcalibur software as .txt ﬁles and imported
directly into the Apm2s tool for further downstream processing.
Data Processing and Analysis. Details available in
Supporting Information (SI).
■ RESULTS AND DISCUSSION
In our study cisplatin was incubated with ubiquitin in pure
water (pH 6.1), which retains the protein in a native-like state
(Figure S5, SI).28,30 Top-down MS/MS via collision induced
dissociation (CID) was applied on ubiquitin incubated with
cisplatin for 18 h at 37 °C. The [7H + Ubi + PtN2H6]
9+ and
[8H + Ubi + PtN2H6]
10+ precursor ions were selected for
fragmentation and a list of more than 200 metalated fragment
ions were assigned with similarity scores above 80% from the
tool analysis (Tables S3 and S4, SI). The Apm2s tool uses
protein/peptide sequences with user deﬁned modiﬁcations
incorporating any element in the periodic table (for a detailed
description see the SI). For top-down MS speciﬁcally, the tool
identiﬁes a, b, c, x, y, and z fragment ions and, importantly, also
identiﬁes internal fragments which, to the best of our
knowledge, other automated matching solutions do not allow.
Surprisingly, the metalated ions found span the full sequence
of ubiquitin (Figure 1B) and, consequently, we conducted a
closer analysis to identify the most likely binding residues.
Considering the amino acid side chains containing lone pairs
which can coordinate to the metal center (side chains with
carboxylic acid, phenol, amino, or sulfur groups) and the
incubation pH of 6.1 (causing protonation of amine side chains
but leaving carboxylic acid side chains deprotonated), a total of
14 possible platinum coordination sites were identiﬁed (Figure
2). From the crystal structure representation (Figure 2), most
amino acid side chains are pointing outward toward solvent
allowing access for metal binding. From the CID fragments
obtained, platinum potentially binds to all 14 sites. This ﬁnding
is also supported that up to seven platinated adducts are
detected after 18 h incubation of ubiquitin with a 30-fold excess
of cisplatin (Figure S4, SI), demonstrating the presence of
multiple binding sites of platinum on ubiquitin.
As mentioned above, previous studies had identiﬁed only one
platinum binding site (Met1) from top-down MS and up to
four (Met1, Thr12, Thr14, and Asp32) via bottom-up
approaches,21,27,28 the larger number in the latter possibly
due to detachment and rebinding reactions taking place during
the digestion process. The identiﬁcation of up to 14 binding
sites via top-down MS highlights the importance of automated
identiﬁcation of all possible metalated ion species, including
metalated internal fragments which are otherwise obscured.
Moreover, these ﬁndings highlight the complexity of metal-
lodrug binding to proteins which are probably mediated by
multidentate interactions (see SI). The results from top-down
studies were conﬁrmed by bottom-up experiments where
metalated digest fragments spanning the full sequence of
ubiquitin were observed (Figure S6, SI), indicative of the same
14 diﬀerent binding sites. Analysis of the bottom-up data was
similarly performed by the Apm2s tool, which is amenable to
matching of enzymatically digested protein fragments.
The abundance of metalated/unmetalated CID fragments
was analyzed to establish whether there is any preference of
cisplatin binding along the ubiquitin sequence. Starting from
the N-terminus, fragment ions from residues 1−39 were named
N-ter, and those including residues 40−76 were named C-ter,
with all other fragment ions named M for middle
(nomenclature detailed in Figure 3A). Upon platination,
there is a clear shift from a near 1:1 ratio of N-ter: C-ter
fragments in free ubiquitin to a 7:3 ratio of N-ter:C-ter in
platinum bound ubiquitin, showing a preference of formation of
N-ter metalation (Figure 3, B). This diﬀerence indicates that
platination occurs preferentially on the N-terminal half of
ubiquitin, which may be rationalized from isoelectric point (PI)
calculations of both halves of the protein. The N-terminal
region of ubiquitin, which contains more acidic side chain
amino acids, has a PI of 4.62, giving it a more negative polarity
than the C-terminal region with a PI of 9.34 (Figure 4).
Considering that cisplatin is a prodrug and that aquation
involves formation of the active cationic intermediates (Figure
5)31 attraction to the negatively charged region of ubiquitin
would be expected, leading to the observed binding preference.
Upon platinum binding, there is an increase in the
proportion of M fragments as a fraction of total fragments,
from 66% in free ubiquitin to 88% in metalated ubiquitin
(Figure 3B). This shift in distribution is also accompanied with
an increase in the average length of fragment ions obtained
upon metal binding (Figure 3C). From the availability of up to
14 diﬀerent platinum binding sites on ubiquitin and the
formation of ions containing up to seven platinums in the
Figure 4. Ribbon crystal structure of bovine ubiquitin indicating the
N-ter and C-ter portions of the protein (colored in translucent red and
light blue, respectively) with isoelectric point values labeled. Acidic
amino acid residues (Glu and Arg) are labeled in red.
Figure 5. Aquation reactions of cisplatin.
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presence of 30-fold excess of drug (Figure S4, SI), presumably
binding of cisplatin to ubiquitin occurs mostly in a bi-, tri-, and
tetra-dentate manner. Such binding potentially connects
peptide fragments, thus during CID fragmentation of the
peptide backbone these connected fragments stay intact leading
to the observed increased proportion of M fragments and
higher average lengths of metalated fragments. Alternatively
part of the CID energy could be spent on dissociation of
ligands coordinated to the platinum center, leaving less energy
available for fragmentation of the protein.
As validation of the Apm2s tool on a diﬀerent metal-protein
system, we used the tool to study the interaction of a
ruthenium(II) drug, RAPTA-C, on the 17 kDa protein
myoglobin (data provided in the SI). The tool is able to detect
ruthenium adducts and loss of heme on myoglobin highlighting
its applicability to larger proteins and diﬀerent metals. Studies
on more complex systems (larger proteins, diﬀerent fragmenta-
tion methods, and various protein modiﬁcations) will be carried
out in the future to improve the tools performance.
■ CONCLUSIONS
This study highlights the importance of matching all MS/MS
fragment peaks including internal fragments when performing
top-down MS experiments to study metallodrug−protein
interactions. Exhaustive matching using the Apm2s tool
disclosed here provides an abundance of data which can give
valuable insight into metal-protein binding. Speciﬁcally, we
have shown that cisplatin binding to ubiquitin appears to be far
more complex than currently thought, with evidence to support
up to 14 diﬀerent binding sites, with a preference for the
negatively charged, accessible regions of the protein. These
ﬁndings have implications in design of targeted metallodrugs
where the complexity and promiscuity of metallodrug binding
to proteins necessitates careful consideration of the metal
center and associated ligands to achieve the desired selectivity.
Besides our application, the Apm2s tool could also be used to
study metal toxins and should greatly facilitate metallomics
studies, which are currently attracting considerable attention in
both the cause and prevention of various diseases. For the
broader MS community, the analysis tool can be applied to
studies involving proteins modiﬁed with virtually any element
in the periodic table and would greatly facilitate data analysis
for such applications.
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(5) Melnikov, S. V.; Söll, D.; Steitz, T. A.; Polikanov, Y. S. Nucleic
Acids Res. 2016, 44, 4978−4987.
(6) Quintanar, L.; Rivillas-Acevedo, L. Methods Mol. Biol. 2013, 1008,
267−297.
(7) Murray, B. S.; Menin, L.; Scopelliti, R.; Dyson, P. J. Chem. Sci.
2014, 5, 2536−2545.
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